WallStreetZenWallStreetZen

NASDAQ: ESPR
Esperion Therapeutics Inc Stock Ownership - Who owns Esperion Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Esperion Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Benjamin HalladayChief Financial Officer2025-07-1711$1.12
$12.27Sell
Benjamin LookerGeneral Counsel2025-07-171,304$1.13
$1.47kSell
Benjamin HalladayChief Financial Officer2025-06-177,229$1.15
$8.33kSell
Benjamin LookerGeneral Counsel2025-06-176,422$1.15
$7.40kSell
Sheldon L. KoenigPresident and CEO2025-06-1730,474$1.11
$33.80kSell
Eric WarrenChief Commercial Officer2025-04-17108$0.98
$105.62Sell
Benjamin HalladayChief Financial Officer2025-04-178$0.96
$7.71Sell
Eric WarrenChief Commercial Officer2025-03-182,433$1.49
$3.62kSell
Sheldon L. KoenigPresident and CEO2025-03-1813,047$1.50
$19.62kSell
Benjamin HalladayChief Financial Officer2025-03-183,535$1.48
$5.24kSell

1 of 3

ESPR insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ESPR insiders and whales buy or sell their stock.

ESPR Shareholders

What type of owners hold Esperion Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Blackrock Inc7.31%14,493,020$17.97MInstitution
Vanguard Group Inc5.80%11,487,729$14.24MInstitution
Wasatch Advisors LP5.52%10,931,257$13.55MInstitution
Bellevue Group Ag4.89%9,694,064$12.02MInstitution
Two Seas Capital LP3.50%6,930,871$8.59MInstitution
Morgan Stanley3.32%6,586,632$8.17MInstitution
State Street Corp2.29%4,548,248$5.64MInstitution
Target N. V. Biotech2.26%4,477,964$5.55MInsider
Geode Capital Management LLC2.24%4,446,297$5.51MInstitution
Alta Partners VIII LP2.15%4,262,156$5.29MInsider

1 of 3

ESPR vs Pharmaceutical Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ESPR57.14%20.68%Net SellingNet Selling
TKNO11.45%64.16%Net SellingNet Selling
ACB13.99%0.00%
CGC7.47%58.13%Net SellingNet Selling
OGI4.61%0.00%
View Top Pharmaceutical Stocks

Esperion Therapeutics Stock Ownership FAQ

Who owns Esperion Therapeutics?

Esperion Therapeutics (NASDAQ: ESPR) is owned by 57.14% institutional shareholders, 20.68% Esperion Therapeutics insiders, and 22.19% retail investors. Target N. V. Biotech is the largest individual Esperion Therapeutics shareholder, owning 4.48M shares representing 2.26% of the company. Target N. V. Biotech's Esperion Therapeutics shares are currently valued at $5.24M.

If you're new to stock investing, here's how to buy Esperion Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.